Low Mean Cell Haemoglobin is a Valuable Parameter of Thrombotic Risk Stratification in Patients with Polycythemia Vera

Objectives: Thrombosis is a leading cause of morbidity and mortality in patients with Philadelphia negative chronic myeloproliferative neoplasms (MPNs). There are many thrombosis risk stratifications used in this patient group taking into consideration the age, thrombosis history and cardiovascular factors (hypertension, hypercholesterinaemia, hyper-trigliceridaemia, thrombocytosis, smoking and diabetes mellitus). In this work we evaluated the possible role of iron deficiency in thrombotic events (TE) of the polycythaemia vera (PV) patients. Methods: We considered the low mean cell haemoglobin (MCH <28 pg) value as a parameter to assess the iron deficiency in the multicentre database (15 Hungarian haematology centres) of our HUMYPRON GROUP (Hungarian MPN Working Group). The MCH values, recorded at the time of diagnosis of 296 patients with polycythemia vera, were retrospectively analysed.Results: The low MCH, at the diagnosis, was found to be a risk factor for thrombotic events occurring after diagnosis (OR: 1.966). It was also shown as an additive and independent parameter in the Tefferi high-risk patient groups, and combining it with Tefferi risk stratification an extremely high thrombotic risk group could be determined (Nagelkerke R square: 0.084). We have supposed that low MCH in PV reveals a disease form featured with a high proliferation activity. Our hypothesis was confirmed with a sub-study (n=52) showing that the high JAK2V617F allele burden was significantly correlated with the low MCH (p=0.005) and the high white blood cell count (WBC) (p<0.001).Conclusions: Iron deficiency, existing at the time of diagnosis of PV, was proven to be a risk factor for imminent thrombotic events. The low MCH was found to be a strong additive factor when it was combined with the known thrombotic risk stratification systems. The low MCH showed significant correlation with the high JAK2V617F allele burden.

[1]  T. Barbui,et al.  Diagnostic impact of the 2016 revised who criteria for polycythemia vera , 2017, American journal of hematology.

[2]  S. Verstovsek,et al.  Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy. , 2017, Leukemia research.

[3]  J. How,et al.  Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease , 2017, Therapeutic advances in hematology.

[4]  C. Bödör,et al.  Increased Lipocalin 2 level may have important role in thrombotic events in patients with polycythemia vera and essential thrombocythemia. , 2016, Leukemia research.

[5]  T. Barbui,et al.  Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk‐stratification and management , 2015, American journal of hematology.

[6]  R. Kralovics,et al.  Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. , 2013, Blood.

[7]  A. Falanga,et al.  Thrombotic disease in the myeloproliferative neoplasms. , 2012, Hematology. American Society of Hematology. Education Program.

[8]  T. Barbui,et al.  Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? , 2009, Blood.

[9]  Manuela M. Santos,et al.  Anemia upregulates lipocalin 2 in the liver and serum. , 2008, Blood cells, molecules & diseases.

[10]  R. Silver,et al.  The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. , 2008, Blood.

[11]  L. Di Gennaro,et al.  Prevention of thrombosis in polycythemia vera and essential thrombocythemia , 2008, Haematologica.

[12]  G. Lippi,et al.  Iron and thrombosis , 2007, Annals of Hematology.

[13]  H. Hasselbalch,et al.  The JAK2 V617F mutation involves B‐ and T‐lymphocyte lineages in a subgroup of patients with Philadelphia‐chromosome negative chronic myeloproliferative disorders , 2007, British journal of haematology.

[14]  K. Mori,et al.  Dual action of neutrophil gelatinase-associated lipocalin. , 2007, Journal of the American Society of Nephrology : JASN.

[15]  T. Barbui,et al.  Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  P. Campbell,et al.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.

[17]  M. Cazzola,et al.  Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. , 2004, The American journal of medicine.

[18]  J. Bale,et al.  Cerebral Sinovenous Thrombosis in Children: Another Reason to Treat Iron Deficiency Anemia , 2004, Journal of child neurology.

[19]  Christian Thomas,et al.  Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. , 2002, Clinical chemistry.

[20]  D. Dietzen,et al.  Clinical utility of the reticulocyte hemoglobin content in the diagnosis of iron deficiency. , 2002, Blood.

[21]  I. Scharrer,et al.  Central Retinal Vein Occlusion and Nonarteritic Ischemic Optic Neuropathy in 2 Patients with Mild Iron Deficiency Anemia , 2001, Ophthalmologica.

[22]  M. Tekin,et al.  Possible effects of antioxidant status on increased platelet aggregation in childhood iron‐deficiency anemia , 2001, Pediatrics international : official journal of the Japan Pediatric Society.

[23]  P. Venge,et al.  Lipocalins as biochemical markers of disease. , 2000, Biochimica et biophysica acta.

[24]  R. Armen,et al.  Ligand preference inferred from the structure of neutrophil gelatinase associated lipocalin. , 2000, Biochemistry.

[25]  L. Schaefer,et al.  Hypochromic red blood cells and reticulocytes. , 1999, Kidney international. Supplement.

[26]  J. Salonen,et al.  Association between body iron stores and the risk of acute myocardial infarction in men. , 1998, Circulation.

[27]  C. Derdeyn,et al.  Carotid artery thrombus associated with severe iron-deficiency anemia and thrombocytosis. , 1996, Stroke.

[28]  R Chirillo,et al.  Simultaneous measurement of reticulocyte and red blood cell indices in healthy subjects and patients with microcytic and macrocytic anemia. , 1995, Blood.

[29]  H. Macdonald.  High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. , 1993, Circulation.

[30]  H. Sengeløv,et al.  Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. , 1993, The Journal of biological chemistry.

[31]  Heikki Korpela,et al.  High Stored Iron Levels Are Associated With Excess Risk of Myocardial Infarction in Eastern Finnish Men , 1992, Circulation.

[32]  R. Lauffer.  Iron stores and the international variation in mortality from coronary artery disease. , 1991, Medical hypotheses.

[33]  G. Stehle,et al.  Noninfectious thrombosis of the superior sagittal sinus in a patient with iron deficiency anemia. , 1991, Stroke.

[34]  J. Goldberg,et al.  Treatment of polycythemia vera with hydroxyurea , 1984, American journal of hematology.

[35]  J. Sullivan.  IRON AND THE SEX DIFFERENCE IN HEART DISEASE RISK , 1981, The Lancet.

[36]  T. Kirkham,et al.  Central retinal vein occlusion complicating iron deficiency anaemia. , 1971, The British journal of ophthalmology.

[37]  M. Moizs,et al.  [Low mean cell hemoglobin is a reliable marker for iron deficiency screening]. , 2016, Orvosi hetilap.

[38]  U. Miklós,et al.  negative chronic myeloproliferative neoplasia registry in Hungary , 2016 .

[39]  G. Rasool,et al.  Automated Measurement of Red Blood Cell Microcytosis and Hypochromia in Iron Deficiency and Beta Thalassemia Trait , 2016 .

[40]  D. Keene,et al.  Iron deficiency: a cause of stroke in infants and children. , 1997, Pediatric neurology.